Quince Therapeutics Inc. (NASDAQ:QNCX) announced that it has resolved its outstanding debt with the European Investment Bank through a settlement payment of $5.5 million, according to a company press release.
The payment clears approximately $16.4 million in debt obligations as of March 27, 2026. With the settlement completed, both the agreement and the original loan obligations have been fully satisfied and discharged. As of the most recent quarter, the company reported total debt of about $18 million. Quince currently holds more cash than debt on its balance sheet, although its cash reserves are being rapidly used.
“By settling Quince’s debt obligations, we believe that we have removed a substantial overhang that was constraining the company’s flexibility and ability to pursue strategic alternatives,” said Dirk Thye, the company’s Chief Executive Officer and Chief Medical Officer.
The company is currently undergoing a corporate restructuring and reviewing a range of strategic alternatives. These options may include a merger, reverse merger, asset divestiture, or other strategic transactions.
Quince Therapeutics is a publicly traded company presently focused on restructuring efforts aimed at maximizing shareholder value. Its shares recently traded at $0.09, giving the company a market capitalization of about $4.88 million. The stock has declined roughly 94% year-to-date.
In other recent developments, Quince Therapeutics reported results from its Phase 3 NEAT clinical trial evaluating its lead drug candidate, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP). The trial did not meet its primary or secondary endpoints in patients with Ataxia-Telangiectasia, prompting the company to reassess its strategic direction.
Following the trial outcome, Quince began exploring strategic alternatives, including possible merger transactions, and appointed LifeSci Capital as its exclusive financial advisor. The developments also led to analyst rating changes, with Lucid Capital Markets downgrading the stock from Buy to Sell and assigning a price target of $0, while D. Boral Capital lowered its rating from Buy to Hold.
Separately, Quince Therapeutics received notices from the Nasdaq Stock Market indicating it is not currently in compliance with listing requirements because its share price has remained below the $1.00 minimum threshold. The company has until September 14, 2026, to regain compliance.
Despite these challenges, Quince Therapeutics said it is actively evaluating multiple paths to enhance shareholder value, which could include partnerships, joint ventures, or other strategic transactions. These efforts reflect the company’s attempt to navigate its current financial and strategic challenges.